Meet some of the people featured in the July/August 2020 issue of The Scientist.

Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.

There’s a new cell-based cancer immunotherapy on the block.

Injecting the seasonal flu vaccine directly into clumps of malignant cells recruits immune cells to confront the cancer.

A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.

This previously unknown mechanism for spotting foreign genetic material in the cytoplasm launches antiviral defenses even when the well-known immune mediator STING is absent.

The immunotherapy induces a form of cell death in leukemia cells in mice that triggers cytokine release syndrome, a dangerous inflammatory reaction that occurs in some patients.

The Oxford researcher’s work on lipid and peptide antigens revealed key mechanisms in inflammation, immunotherapy, and vaccination, which are being pursued in clinical trial treatments.

Scientists show the approach can kill cells that cause hardening of heart tissue in mice.